An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

Abroad (travel likely)Recruiting

Conditions

Triple-Negative Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Severance Hospital, Yonsei University Health System, Seoul, Seodaemun-gu, South Korea
Contact: Study coordinator (Gun Min Kim) · gmkim77@yuhs.ac · 02-2228-8126
Gangnam Severance Hospital, Yonsei University Health System, Seoul, South Korea
Contact: Study coordinator (Jee Hung KIM) · OK8504@yuhs.ac · +82 02-2019-3305

Study leads

Gun Min Kim, Professor
Principal Investigator
Severance Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Solid Tumor, Adult · Colorectal Cancer · Non Small Cell Lung Cancer

Abroad (travel likely)Recruiting

Gilbert, United States · Phoenix, United States

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Locally Advanced Triple Negative Breast Cancer · TNBC - Triple-Negative Breast Cancer

Abroad (travel likely)RecruitingEARLY_PHASE1

New York, United States

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Aarau, Switzerland · Basel, Switzerland